Sunbeam Capital Management LLC Acquires Shares of 1,823 Eli Lilly and Company (NYSE:LLY)

Sunbeam Capital Management LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,823 shares of the company’s stock, valued at approximately $1,407,000. Eli Lilly and Company comprises 1.3% of Sunbeam Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding.

Other institutional investors also recently made changes to their positions in the company. FPC Investment Advisory Inc. boosted its holdings in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $48,000. Compass Financial Services Inc bought a new position in Eli Lilly and Company during the 4th quarter worth $50,000. Fiduciary Advisors Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter worth $58,000. Finally, Bellwether Advisors LLC acquired a new stake in Eli Lilly and Company in the fourth quarter worth $66,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 0.2%

Shares of Eli Lilly and Company stock opened at $713.99 on Friday. The business has a fifty day simple moving average of $789.29 and a 200-day simple moving average of $803.19. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The firm has a market cap of $676.67 billion, a price-to-earnings ratio of 60.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter last year, the firm posted $2.58 earnings per share. Eli Lilly and Company’s revenue was up 45.2% compared to the same quarter last year. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.84%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target for the company. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and lowered their target price for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, Hsbc Global Res downgraded Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,011.37.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.